Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

5 Mar 2013 13:19

RNS Number : 2731Z
Venn Life Sciences Holdings PLC
05 March 2013
 



 

 

Standard Form TR-1Voting rights attached to shares- Article 12(1) of directive 2004/109/ECFinancial instruments - Article 11(3) of the Commission Directive 2007/14/EC[i]

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached [ii]:

Venn Life Sciences

 

2. Reason for the notification (please tick the appropriate box or boxes):

[x ] an acquisition or disposal of voting rights

[ ] an acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

[ ] an event changing the breakdown of voting rights

3. Full name of person(s) subject to the notification obligation[iii]:

Davycrest Nominees

 

4. Full name of shareholder(s) (if different from 3.)[iv]:

 

5. Date of the transaction and date on which the threshold is crossed or reached[v]:

13 February 2013

 

6. Date on which issuer notified;

04 March 2013

 

7. Threshold(s) that is/are crossed or reached:

3%

8. Notified details:

 

A) Voting rights attached to shares

Class/type of shares (if possible using the ISIN CODE)

Situation previous to the Triggering transaction [vi]

Below 3%

Resulting situation after the triggering transaction[vii]

Number of Shares[viii]

Number of Voting rights[ix]

Number of shares[x]

Number of voting rights[xi]

% of voting rights

Direct

Direct[xii]

Indirect[xiii]

Direct

Indirect

GB00B9275X97

Above 3%

621,667

 

621,667

3.09%

SUBTOTAL A (based on aggregate voting rights)

Above 3%

621,667

621,667

 

3.09%

 

B) Financial Instruments

Resulting situation after the triggering transaction[xiv]

Type of financial instrument

Expiration Date[xv]

Exercise/Conversion Period/ Date[xvi]

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

SUBTOTAL B (in relation to all expiration dates)

 

Total (A+B)

number of voting rights

% of voting rights

621,667

 

3.09%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instrumentsare effectively held, if applicable[xvii]:

10. In case of proxy voting:[name of the proxy holder] will cease to hold [number] voting rights as of [date].

11. Additional information:

Done at [place] on [date].

 


[i] This form is to be sent to the issuer or underlying issuer and to be filed with the competent authority.

 

[ii] Either the full name of the legal entity or another method for identifying the issuer or underlying issuer, provided it is reliable and accurate.

 

[iii] This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in Article 10 (b) to (h) of Directive 2004/109/EC; (c) all the parties to the agreement referred to in Article 10 (a) of that Directive, or (d) the holder of financial instruments entitled to acquire shares already issued to which voting rights are attached, as appropriate.

 

In relation to the transactions referred to in points (b) to (h) of Article 10 of that Directive, the following list is provided as indication of the persons who should be mentioned:

 

- in the circumstances foreseen in letter (b) of Article 10 of that Directive, the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

 

- in the circumstances foreseen in letter (c) of Article 10 of that Directive, the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

 

- in the circumstances foreseen in letter (d) of Article 10 of that Directive, the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

 

- in the circumstances foreseen in letter (e) of Article 10 of that Directive, the controlling natural person or legal entity and, provided it has a notification duty at an individual level under Article 9, under letters (a) to (d) of Article 10 of that Directive or under a combination of any of those situations, the controlled undertaking;

 

- in the circumstances foreseen in letter (f) of Article 10 of that Directive, the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

 

- in the circumstances foreseen in letter (g) of Article 10 of that Directive, the natural person or legal entity that controls the voting rights;

 

- in the circumstances foreseen in letter (h) of Article 10 of that Directive, the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion.

[iv] Applicable in the cases provided for in Article 10 (b) to (h) of Directive 2004/109/EC. This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to in Article 10 of that Directive unless the holdings of the shareholder would be lower than 5% of the total number of voting rights.

 

[v] The date of the transaction should normally be, in the case of an on exchange transaction, the date on which the matching of orders occurs; in the case of an off exchange transaction, date of the entering into an agreement. 

 

The date on which threshold is crossed should normally be the date on which the acquisition, disposal or possibility to exercise voting rights takes effect. For passive crossings, the date when the corporate event took effect.

 

[vi] Please refer to the situation disclosed in the previous notification. In case the situation previous to the triggering transaction was below 3%, please state "below 3%".

 

[vii] If the holding has fallen below the minimum threshold, the notifying party should not be obliged to disclose the extent of the holding, only that the new holding is below 3%.

 

For the case provided for in Article 10(a) of Directive 2004/109/EC, there should be no disclosure of individual holdings per party to the agreement unless a party individually crosses or reaches an Article 9 threshold. This applies upon entering into, introducing changes to or terminating an agreement.

 

[viii] To be used in Member States where applicable.

 

[ix] Direct and indirect.

 

[x] To be used in Member States where applicable.

 

[xi] In case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.

 

[xii] Voting rights attached to shares held by the notifying party (Article 9 of Directive 2004/109/EC).

 

[xiii] Voting rights held by the notifying party independently of any holding of shares (Article 10 of Directive 2004/109/EC).

 

[xiv] If the holding has fallen below the minimum threshold, the notifying party should not be obliged to disclose the extent of the holding, only that the new holding is below 3%.

 

[xv] Date of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.

 

[xvi] If the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].

 

[xvii] The notification should include the name(s) of the controlled undertakings through which the voting rights are held. The notification should also include the amount of voting rights and the percentage held by each controlled undertaking, insofar as individually the controlled undertaking holds 3% or more, and insofar as the notification by the parent undertaking is intended to cover the notification obligations of the controlled undertaking.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEADDSEFKDEFF
Date   Source Headline
25th Oct 20227:00 amRNSChange of name to hVIVO plc effective
20th Oct 20227:00 amRNSCapital Markets Day
18th Oct 20227:00 amRNSCFO appointment & change of Board roles
30th Sep 20227:00 amRNSPositive in vitro results for FLU-v published
29th Sep 20229:30 amRNSDirector dealings
27th Sep 20227:00 amRNSUpcoming Scientific Presentations
15th Sep 20227:00 amRNSComment regarding press speculation
8th Sep 20227:01 amRNSInterim results and trading update
8th Sep 20227:00 amRNSIntention to change name to hVIVO plc
1st Sep 20227:20 amRNSCAP accreditation
25th Aug 20227:00 amRNSNotice of results
22nd Aug 20227:00 amRNS£10.4m contract with existing Big Pharma client
4th Aug 20227:00 amRNS£6.2m Influenza human challenge study contract
5th Jul 20221:17 pmRNSResult of AGM
30th Jun 20227:00 amRNSOmicron human challenge model
14th Jun 20227:00 amRNS£7.2m RSV human challenge study contract
10th Jun 202212:13 pmRNSBoard appointment amendment
10th Jun 202212:00 pmRNSAnnual Report and Notice of AGM
8th Jun 20227:00 amRNSBoard appointment
7th Jun 20229:05 amRNSSecond Price Monitoring Extn
7th Jun 20229:00 amRNSPrice Monitoring Extension
7th Jun 20227:00 amRNSFinal results
1st Jun 20227:00 amRNSGBP14.7m influenza contract signed
26th May 20227:00 amRNSCompletion of Nominated Adviser due diligence
24th May 20227:00 amRNSNotice of results
18th May 20227:00 amRNS£7.3m Influenza human challenge study contract win
12th May 20227:00 amRNSWellcome publication
5th May 20227:00 amRNSVaccine field study contract
4th May 20227:00 amRNSChallenge virus manufacturing contract
4th May 20227:00 amRNSComment re: speculation
28th Apr 20227:00 amRNSAppointment of Nominated Adviser and Joint Broker
13th Apr 20227:00 amRNSProposal to Distribution in Specie Shareholders
12th Apr 202212:00 pmRNSPresentation at World Vaccine Congress
6th Apr 20224:35 pmRNSPrice Monitoring Extension
6th Apr 20222:05 pmRNSSecond Price Monitoring Extn
6th Apr 20222:01 pmRNSPrice Monitoring Extension
6th Apr 202211:05 amRNSSecond Price Monitoring Extn
6th Apr 202211:00 amRNSPrice Monitoring Extension
31st Mar 202210:05 amRNSCharacterisation Study results in Nature Medicine
25th Mar 20227:00 amRNS£5m RSV human challenge study contract win
9th Mar 20224:41 pmRNSSecond Price Monitoring Extn
9th Mar 20224:37 pmRNSPrice Monitoring Extension
8th Mar 20227:00 amRNSTrading Update and screening facilities expansion
7th Mar 20222:06 pmRNSSecond Price Monitoring Extn
7th Mar 20222:00 pmRNSPrice Monitoring Extension
7th Mar 202211:06 amRNSSecond Price Monitoring Extn
7th Mar 202211:00 amRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSInvestor Presentations
24th Feb 20227:00 amRNSCEO Appointment
22nd Feb 20227:00 amRNSFDA Breakthrough Designation for Big Pharma RSV

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.